Ironwood Pharmaceuticals (IRWD) Amortization of Deferred Charges (2013 - 2026)

Ironwood Pharmaceuticals (IRWD) has 14 years of Amortization of Deferred Charges data on file, last reported at $444000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges rose 8.56% year-over-year to $444000.0; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 8.43% YoY), and the FY2025 full-year result was $1.7 million, up 8.34% from the prior year.
• Amortization of Deferred Charges climbed to $444000.0 in Q1 2026, from $435000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $587000.0 in Q4 2023 to a low of $378000.0 in Q1 2024.
• A 5-year average of $447235.3 and a median of $418000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges slumped 93.49% in 2022 and jumped 46.75% in 2023, its largest moves.
• Tracing IRWD's Amortization of Deferred Charges over 5 years: stood at $400000.0 in 2022, then jumped by 46.75% to $587000.0 in 2023, then sank by 31.52% to $402000.0 in 2024, then increased by 8.21% to $435000.0 in 2025, then rose by 2.07% to $444000.0 in 2026.
• Business Quant data shows IRWD's Amortization of Deferred Charges at $444000.0 in Q1 2026, $435000.0 in Q4 2025, and $426000.0 in Q3 2025.